Press release
Compugen to Present New Clinical Data at SITC 2024
HOLON, Israel, Oct. 7, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in
About this update from Compugen Ltd.
HOLON, Israel , Oct. 7, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that new clinical data supporting the anti-tumor activity and safety of the triple combination COM701, COM902 and pembrolizumb in heavily pre-treated patients with platinum resistant ovarian cancer will be presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between November 8-10, 2024 , in Houston, Texas . Poster presentation details: Abstract Title: Triple blockade of DNAM-1axis with COM701 (anti-PVRIG) + COM902 (anti-TIGIT) + pembrolizumab shows preliminary antitumor activity in patients with platinum resistant ovarian cancer, interim results of Phase I trial Abstract number: 985 Presenter: Dr. Oladapo Yeku , Medical Oncologist, Massachusetts General Hospital Date : Friday, November 8, 2024 About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform ( Unigen TM) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which has been granted IND clearance from the FDA, is licensed to Gilead. Compugen is headquartered in Israel , with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Company contact: Yvonne Naughton , Ph.D.VP, Head of Investor Relations and Corporate CommunicationsEmail: [email protected] Tel: +1 (628) 241-0071 View original content: https://www.prnewswire.com/news-releases/compugen-to-present-new-clinical-data-at-sitc-2024-302268683.html SOURCE Compugen Ltd.